A treatment algorithm for neuropathic pain

Clinical Therapeutics

Volumn 26, Issue 7, 2004, Pages 951-979

  Namaka, Mike ^a,b   Gramlich, Colin R ^a   Ruhlen, Dana ^a   Melanson, Maria ^b   Sutton, Ian ^b   Major, Joanne ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

clinical symptoms; dorsal root ganglia; neuronal hyperexcitability; neuropathic pain; treatment algorithm

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CONTRACEPTIVE AGENT; DESIPRAMINE; DOPAMINE; FLUOXETINE; GABAPENTIN; IBUPROFEN; IMIPRAMINE; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; ALGORITHM; ALLERGIC REACTION; ANALGESIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ATAXIA; BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CROSS ALLERGY; DEPRESSION; DIABETIC NEUROPATHY; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG CLASSIFICATION; DRUG DEPENDENCE; DYSMENORRHEA; DYSPEPSIA; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; GINGIVA DISEASE; HEADACHE; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEART INFARCTION; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MOOD DISORDER; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTPATIENT DEPARTMENT; PATIENT CARE; PEPTIC ULCER; POSTHERPETIC NEURALGIA; RASH; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; STOMACH PAIN; SWEATING; TECHNIQUE; TERATOGENESIS; TREMOR; TRIGEMINUS NEURALGIA; URINE RETENTION; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 4344674986     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90171-3     Document Type: Article

References (214)

1. Millan M.J. The induction of pain: An integrative review. Prog Neurobiol. 57:1999;1-164
2. Willis W.D. Jr. The pain system. The neural basis of nociceptive transmission in the mammalian nervous system. Pain Headache. 8:1985;1-346
3. Stankus S.J., Dlugopolski M., Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 61:2000;2437-2448
4. Maloni H.W. Pain in multiple sclerosis: An overview of its nature and management. J Neurosci Nurs. 32:2000;139-144
5. McCarthy P.W., Lawson S.N. Cell type and conduction velocity of rat primary sensory neurons with calcitonin gene-related peptide-like immunoreactivity. Neuroscience. 34:1990;623-632
6. Won R., Lee B.H., Park S., et al. Role of different peripheral components in the expression of neuropathic pain syndrome. Yonsei Med J. 41:2000;354-361
7. Winkelstein B.A., Rutkowski M.D., Sweitzer S.M., et al. Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J Comp Neurol. 439:2001;127-139
8. Ignatowski T.A., Covey W.C., Knight P.R., et al. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 841:1999;70-77
9. Russell J.W., Sullivan K.A., Windebank A.J., et al. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis. 6:1999;347-363
10. Honma H., Podratz J.L., Windebank A.J. Acute glucose deprivation leads to apoptosis in a cell model of acute diabetic neuropathy. J Peripher Nerv Syst. 8:2003;65-74
11. Srinivasan S., Stevens M., Wiley J.W. Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 49:2000;1932-1938
12. Schmeichel A.M., Schmelzer J.D., Low P.A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes. 52:2003;165-171
13. Campana W.M., Myers R.R. Exogenous erythropoeitin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci. 8:2003;1497-1506
14. Schenker M., Kraftsik R., Glauser L., et al. Thyroid hormone reduces the loss of axotomized sensory neurons in dorsal root ganglia after sciatic nerve transection in adult rat. Exp Neurol. 184:2003;225-236
15. Woolf C.J., Shortland P., Coggeshall R.E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 355:1992;75-78
16. Ribbers G.M., Geurts A.C., Stam H.J., Mulder T. Pharmacologic treatment of complex regional pain syndrome I: A conceptual framework. Arch Phys Med Rehabil. 84:2003;141-146
17. Hains B.C., Klein J.P., Saab C.Y., et al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci. 23:2003;8881-8892
18. Jensen T.S. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur J Pain. 6:(Suppl A):2002;61-68
19. Lossin C., Wang D.W., Rhodes T.H., et al. Molecular basis of an inherited epilepsy. Neuron. 34:2002;877-884
20. Sherwood L. Human Physiology: From Cells to Systems. 4th ed. :2001;Brooks/Cole, Pacific Grove, Ca
21. Wyllie Elaine. The Treatment of Epilepsy: Principles and Practice. 3rd ed. :2001;Lippincott, Williams and Wilkins, Philadelphia
22. Lopes Da Silva F.H., Wadman W.J. Pathophysiology of Epilepsy. Handbook of Clinical Neurology. The Epilepsies: Part 1. 1999;39-81 Elsevier, New York
23. Vinik A.I. Diabetic Neuropathy: A Small-Fiber Disease. 61st Scientific Sessions of the American Diabetes Association. Philadelphia, Pennsylvania :June 22-26, 2001;. Available at: http://www.medscape.com/viewprogram/534
24. Dalakas M.C., Semino-Mora C., Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest. 81:2001;1537-1544
25. Koltzenburg M., Scadding J. Neuropathic pain. Curr. Opin Neurol. 14:2001;641-647
26. Ilse W.K. Neuropathic pain: Mechanisms, diagnosis and treatment. Can J Continuing Med Education. 14:2002;99-108
27. Chong M.S., Bajwa Z.H. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 25:(Suppl 5):2003;S4-S11
28. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs. 17:2003;1031-1043
29. Wallace M.S. Pharmacologic treatment of neuropathic pain. Curr Pain Headache Rep. 5:2001;138-150
30. Abdi S., Lee D.H., Chung J.M. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg. 87:1998;1360-1366
31. Semenchuk M.R., Davis B. Efficacy of sustained-release bupropion in neuropathic pain: An open-label study. Clin J Pain. 16:2000;6-11
32. Max M.B., Kishore-Kumar R., Schafer S.C., et al. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain. 45:1991;3-9
33. Jensen P.G., Larson J.R. Management of painful diabetic neuropathy. Drugs Aging. 18:2001;737-749
34. Kishore-Kumar R., Max M.B., Schafer S.C., et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 47:1990;305-312
35. Richeimer S.H., Bajwa Z.H., Kahraman S.S., et al. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: A survey. Clin J Pain. 13:1997;324-329
36. Barkin R.L., Barkin D. Pharmacologic management of acute and chronic pain: Focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J. 94:2001;756-770
37. Max M.B. Treatment of post-herpetic neuralgia: Antidepressants. Ann Neurol. 35:1994;S50-S53. (Suppl)
38. Einarson A., Lyszkiewicz D., Koren G. The safety of dextromethorphan in pregnancy: Results of a controlled study. Chest. 119:2001;466-469
39. King G, Poston J, Bruce LD, eds. Ottawa: Canadian Pharmacists Association; 2001.
40. Ure D.R., Rodriguez M. Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis. Neuroscience. 111:2002;399-411
41. Bielefeldt K., Ozaki N., Whiteis C., Gebhart G.F. Amitriptyline inhibits voltage-sensitive sodium currents in rat gastric sensory neurons. Dig Dis Sci. 47:2002;959-966
42. 2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol. 68:1990;1414-1418
43. Sawynok J., Reid A.R., Esser M.J. Peripheral antinociceptive action of amitriptyline in the rat formalin test: Involvement of adenosine. Pain. 80:1999;45-55
44. Popik P., Wrobel M., Nowak G. Chronic treatment with antidepressants affects glycine/NMDA receptor function: Behavioral evidence. Neuropharmacology. 39:2000;2278-2287
45. Max M.B., Culnane M., Schafer S.C., et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 37:1987;589-596
46. Watson C.P., Evans R.J., Reed K., et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 32:1982;671-673
47. Vrethem M., Boivie J., Arnqvist H., et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 13:1997;313-323
48. Kalso E., Tasmuth T., Neuvonen P.J. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 64:1996;293-302
49. Kieburtz K., Simpson D., Yiannoutsos C., et al. AIDS Clinical Trial Group 242 Protocol Team. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 51:1998;1682-1688
50. Shlay J.C., Chaloner K., Max M.B., et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 280:1998;1590-1595
51. Sindrup S.H., Gram L.F., Skjold T., et al. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther. 47:1990;509-515
52. Sindrup S.H., Tuxen C., Gram L.F., et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol. 43:1992;251-255
53. Young R.J., Clarke B.F. Pain relief in diabetic neuropathy: The effectiveness of imipramine and related drugs. Diabet Med. 2:1985;363-366
54. Kvinesdal B., Molin J., Froland A., Gram L.F. Imipramine treatment of painful diabetic neuropathy. JAMA. 251:1984;1727-1730
55. Sindrup S.H., Bach F.W., Madsen C., et al. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology. 60:2003;1284-1289
56. Enggaard T.P., Poulsen L., Arendt-Nielsen L., et al. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain. 92:2001;277-282
57. Verma S., Gallagher R.M. The psychopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr Pain Headache Rep. 6:2002;30-39
58. Andreas K., Winifried R. Novel drugs for neuropathic pain. Curr Opin Anaesthesiol. 13:2000;577-583
59. Sindrup S.H., Bjerre U., Dejgaard A., et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 52:1992;547-552
60. Watson C.P., Vernich L., Chipman M., Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology. 51:1998;1166-1171
61. Ray W.A., Meredith S., Thapa P.B., et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 75:2004;234-241
62. Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics. Prescrire Int. 10:2001;25-31
63. Mattia C., Paoletti F., Coluzzi F., Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 68:2002;105-114
64. Semenchuk M.R., Sherman S., Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 57:2001;1583-1588
65. Maina G., Vitalucci A., Gandolfo S., Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: A single-blind study. J Clin Psychiatry. 63:2002;38-43
66. Max M.B., Lynch S.A., Muir J., et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256
67. Okuda K., Takanishi T., Yoshimoto K., Ueda S. Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model. Eur J Anaesthesiol. 20:2003;409-415
68. Ferguson J.M. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 3:2001;22-27
69. Lucena M.I., Carvajal A., Andrade R.J., Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf. 2:2003;249-262
70. Suspected hepatobiliary adverse reactions to the newer antidepressants that affect serotonin neurotransmission. Can Adverse Reaction Newsletter. 13:2003;1-5
71. Withdrawal reactions with paroxetine and other SSRIs. Can Adverse Reaction Newsletter. 13:2003;1-4
72. Dickenson A.H., Matthews E.A., Suzuki R. Neurobiology of neuropathic pain: Mode of action of anticonvulsants. Eur J Pain. 6:(Suppl A):2002;51-60
73. MacPherson R.D. The pharmacological basis of contemporary pain management. Pharmacol Ther. 88:2000;163-185
74. Ambrosio A.F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 27:2002;121-130
75. Soderpalm B. Anticonvulsants: Aspects of their mechanisms of action. Eur J Pain. 6:(Suppl A):2002;3-9
76. Block F., Habermeyer B. Glutamate antagonists for treatment of neuropathic pain. [in German] Schmerz. 17:2003;261-267
77. Taylor C.P., Gee N.S., Su T.Z., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29:1998;233-249
78. Takahashi T., Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature. 366:1993;156-158
79. Field M.J., Hughes J., Singh L. Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol. 131:2000;282-286
80. Trousseau A. Intravenous infusion of phenytoin and neuropathic pain. Clin Med Hotel Dieu. 2:1885;156
81. Chadda V.S., Mathur M.S. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India. 26:1978;403-406
82. Saudek C.D., Werns S., Reidenberg M.M. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 22:1977;196-199
83. Tremont-Lukats I.W., Megeff C., Backonja M.M. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs. 60:2000;1029-1052
84. McCleane G.J. Intravenous infusion of phenytoin relieves neuropathic pain: A randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg. 16:1999;985-988
85. Backonja M.M. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 59:(Suppl 2):2002;S14-S17
86. Covington E.C. Anticonvulsants for neuropathic pain and detoxification. Cleve Clin J Med. 65:(Suppl I):1998;S121-S129
87. Sartor H., Thoden U. Anticonvulsive drugs in therapy of chronic pain - meta-analysis. [in German] Schmerz. 11:1997;411-417
88. Campbell F.G., Graham J.G., Zilkha K.J. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 29:1966;265-267
89. Killian J.M., Fromm G.H. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 19:1968;129-136
90. Harke H., Gretenkort P., Ladleif H.U., et al. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: A double-blinded randomized study. Anesth Analg. 92:2001;488-495
91. Ramsaransing G., Zwanikken C., De K.J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 230:2000;1113
92. Usui T., Saitoh Y., Komada F. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 26:2003;510-517
93. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 16:2002;263-272
94. Chong M.S., Libretto S.E. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 19:2003;59-68
95. Timberlake C. Topiramate, a novel antiepileptic drug in neuropathic pain. Proceedings from the Ninth World Congress on Pain. Vienna, Austria :1999
96. Edwards K.R., Glantz M.J. An evaluation of topiramate in the management of painful diabetic neuropathy. Proceedings from the 17th Annual Scientific Meeting of the American Pain Society. San Diego :1998
97. Zvartau-Hind M., Din M.U., Gilani A., et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 55:2000;1587-1588
98. Haugh M.J., Connor G.S. Trigeminal neuralgia: Pain relief in patients treated with the anticonvulsant topiramate. Proceedings from the 19th Annual Scientific Meeting of the American Pain Society. Atlanta :2000
99. Haugh M.J., Connor G.S. Favorable response of trigeminal neuralgia to the anticonvulsant topiramate: A retrospective study. Cephalgia. 20:2000;379
100. Backonja M.M. Topiramate in the treatment of chronic neuropathic pain: A retrospective chart review. Ann Neurol. 50:(Suppl 1):2001;S63-S64
101. Jenson M.G., Royal M.A., Ward S., et al. Topiramate for the treatment of neuropathic and chronic pain syndromes: An open label trial. AJPM. 12:2002;16-23
102. Edwards K.R., Glantz M.J., Button J., et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Neurology. 54:(Suppl 3):2000;A81
103. Edwards K.R., Glantz M.J., Button J., et al. Presented at: 52nd Annual Meeting of the American Academy of Neurology. April 20-May 6, 2000;. San Diego, Calif
104. Canavero S., Bonicalzi V., Paolotti R. Lack of effect of topiramate for central pain. Neurology. 58:2002;831-832
105. Chengappa K.N., Chalasani L., Brar J.S., et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. Clin Ther. 24:2002;1576-1584
106. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo-controlled trial. Pain. 83:1999;105-107
107. Finnerup N.B., Sindrup S.H., Bach F.W., et al. Lamotrigine in spinal cord injury pain: A randomized controlled trial. Pain. 96:2002;375-383
108. Simpson D.M., McArthur J.C., Olney R., et al. Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial. Neurology. 60:2003;1508-1514
109. Simpson D.M., Olney R., McArthur J.C., et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 54:2000;2115-2119
110. McCleane G.J. Lamotrigine in the management of neuropathic pain: A review of the literature. Clin J Pain. 16:2000;321-326
111. Eisenberg E., Lurie Y., Braker C., et al. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology. 57:2001;505-509
112. Eisenberg E., Alon N., Ishay A., et al. Lamotrigine in the treatment of painful diabetic neuropathy. Eur J Neurol. 5:1998;167-173
113. Zakrzewska J.M., Chaudhry Z., Nurmikko T.J., et al. Lamotrigne (lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo-controlled crossover trial. Pain. 73:1997;223-230
114. Hughes D., Cockerell O.C. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure. 5:1996;89-95
115. Serpell M.G. Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain. 99:2002;557-566
116. Ahn S.H., Park H.W., Lee B.S., et al. Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. Spine. 28:2003;341-346
117. Bone M., Critchley P., Buggy D.J. Gabapentin in postamputation phantom limb pain: A randomized, double-blind placebo-controlled, cross-over study. Reg Anesth Pain Med. 27:2002;481-486
118. Tai Q., Kirshblum S., Chen B., et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: A prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 25:2002;100-105
119. Bosnjak S., Jelic S., Susnjar S., Luki V. Gabapentin for relief of neuropathic pain related to anticancer treatment: A preliminary study. J Chemother. 14:2002;214-219
120. Harden R.N. Gabapentin: A new tool in the treatment of neuropathic pain. Acta Neurol Scand Suppl. 14:1999;43-47
121. Backonja M.M. Gabapetin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 40:(Suppl 6):1999;S57-S59
122. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 280:1998;1831-1836
123. Dallocchio C., Buffa C., Mazzarello P., Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage. 20:2000;280-285
124. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 33:1999;1037-1042
125. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 101:2000;359-371
126. Adelman J.U., Adelman L.C., Von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache. 42:2002;978-983
127. Block F. Gabapentin for therapy of neuropathic pain. [in German] Schmerz. 15:2001;280-288
128. Morello C.M., Leckband S.G., Stoner C.P., et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 159:1999;1931-1937
129. Salinsky M.C., Binder L.M., Oken B.S., et al. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia. 43:2002;482-490
130. Aldenkamp A.P., De Krom M., Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 44:(Suppl 4):2003;21-29
131. DeToledo J.C., Toledo C., DeCerce J., Ramsay R.E. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 19:1997;394-396
132. Blum R.A., Comstock T.J., Sica D.A., et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 56:1994;154-159
133. Bennett W.M., Aronoff G.R., Morrison G., et al. Drug prescribing in renal failure: Dosing guidelines for adults. Am J Kidney Dis. 3:1983;155-193
134. Davis H., Baum C., Graham D.J. Indices of drug misuse for prescription drugs. Int J Addict. 26:1991;777-795
135. Turnheim K. Drug interactions with antiepileptic agents. [in German] Wien Klin Wochenschr. 116:2004;112-118
136. McQuay H., Carroll D., Jadad A.R., et al. Anticonvulsant drugs for management of pain: A systematic review. BMJ. 311:1995;1047-1052
137. Rowbotham M.C., Reisner-Keller L.A., Fields H.L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 41:1991;1024-1028
138. Foldvary N. Treatment issues for women with epilepsy. Neurol Clin. 19:2001;409-425
139. Schluzeck S., Wulf H. Local therapy with capsaicin or ASS in chronic pain. [in German] Schmerz. 11:1997;345-352
140. Rumsfield J.A., West D.P. Topical capsaicin in dermatologic and peripheral pain disorders. DICP. 25:1991;381-387
141. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: A randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 49:2000;574-579
142. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med. 151:1991;2225-2229
143. Biesbroeck R., Bril V., Hollander P., et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther. 12:1995;111-120
144. Watson C.P., Tyler K.L., Bickers D.R., et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 15:1993;510-526
145. Tandan R., Lewis G.A., Badger G.B., Fries T.J. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care. 15:1992;15-18
146. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care. 15:1992;159-165
147. Ellison N., Loprinzi C.L., Kugler J., et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 15:1997;2974-2980
148. Yosipovitch G., Maibach H.I., Rowbotham M.C. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 79:1999;118-121
149. Paice J.A., Ferrans C.E., Lashley F.R., et al. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage. 19:2000;45-52
150. Lynch M.E., Clark A.J., Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 19:2003;323-328
151. Ushida T., Tani T., Kanbara T., et al. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. Reg Anesth Pain Med. 27:2002;524-528
152. Devers A., Galer B.S. Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open-label study. Clin J Pain. 16:2000;205-208
153. Rowbotham M.C., Davies P.S., Verkempinck C., Galer B.S. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 65:1996;39-44
154. Hines R., Keaney D., Moskowitz M.H., Prakken S. Use of lidocaine patch 5% for chronic low back pain: A report of four cases. Pain Med. 3:2002;361-365
155. Brookoff D. Chronic pain: 1. A new disease? Hosp Pract. 35:2000;45-52
156. Zochodne D.W., Max M.B. An old acquaintance: Opiods in neuropathic pain. Neurology. 60:2003;894-895
157. Kalman S., Osterberg A., Sorensen J., et al. Morphine responsiveness in a group of well-defined multiple sclerosis patients: A study with i.v. morphine. Eur J Pain. 6:2002;69-80
158. Leung A., Wallace M.S., Ridgeway B., Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 91:2001;177-187
159. Cherny N.I., Thaler H.T., Friedlander-Klar H., et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology. 44:1994;857-861
160. Rowbotham M.C., Twilling L., Davies P.S., et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 348:2003;1223-1232
161. Gimbel J.S., Richards P., Portenoy R.K. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 60:2003;927-934
162. Watson C.P., Moulin D., Watt-Watson J., et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain. 105:2003;71-78
163. Watson C.P., Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology. 50:1998;1837-1841
164. Raja S.N., Haythornthwaite J.A., Pappagallo M., et al. Opioids versus antidepressants in postherpectic neuralgia: A randomized, placebo-controlled trial. Neurology. 59:2002;1015-1021
165. Garcia J., Altman R.D. Chronic pain states: Pathophysiology and medical therapy. Semin Arthritis Rheum. 27:1997;1-16
166. Nagaoka E., Minami K., Shiga Y., et al. Tramadol has no effect on cortical renal blood flow - despite increased serum catecholamine levels - in anesthetized rats: Implications for analgesia in renal insufficiency. Anesth Analg. 94:2002;619-625
167. Harati Y., Gooch C., Swenson M., et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 50:1998;1842-1846
168. Sindrup S.H., Andersen G., Madsen C., et al. Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain. 83:1999;85-90
169. Sartain J.B., Mitchell S.J. Successful use of oral methadone after failure of intravenous morphine and ketamine. Anaesth Intensive Care. 30:2002;487-489
170. Mancini I., Lossignol D.A., Body J.J. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 12:2000;308-313
171. Latta K.S., Ginsberg B., Barkin R.L. Meperidine: A critical review. Am J Ther. 9:2002;53-68
172. Weiner A.L. Meperidine as a potential cause of serotonin syndrome in the emergency department. Acad Emerg Med. 6:1999;156-158
173. Tegeder I., Geisslinger G., Lotsch J. Therapy with opioids in liver or renal failure. [in German] Schmerz. 13:1999;183-195
174. Remington's Pharmaceutical Sciences. 20th ed. :2000;Mack Publishing Company, Easton, Pa
175. Cryer B. Gastrointestinal safety of low-dose aspirin. Am J Manage Care. 8:(Suppl 22):2002;S701-S708
176. Maetzel A. Motion - cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for stomach: Arguments against the motion. Can J Gastroenterol. 17:2003;335-338
177. Raffa R.B. Pharmacology of oral combination analgesics: Rational therapy for pain. J Clin Pharm Ther. 26:2001;257-264
178. Peripheral vascular disorders. 17th ed. Beers M.H., Berkow R. Merck Manual. 1999;1786-1791 Merck Research Laboratories, Whitehouse Station, NJ
179. Michelis J.J. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: A distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Biol (Paris). 51:2003;167-175
180. Palangio M., Damask M.J., Morris E., et al. Combination hydrocodne and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain. Clin Ther. 22:2000;879-892
181. Generali J., Cada D.J. Dextromethorphan: Neuropathy. Hosp Pharm. 36:2001;421-425
182. Criner T.M., Perdun C.S. Dextromethorphan and diabetic neuropathy. Ann Pharmacother. 33:1999;1221-1223
183. Nelson K.A., Park K.M., Robinovitz E., et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 48:1997;1212-1218
184. Carlsson K.C., Hoem N.O., Mobeg E.R., Mathisen L.C. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 48:2004;328-336
185. Pechnik R.N., Poland R.E. Comparison of the effects of dextromethorphan, dextrophan and levorphanol on the hypothalamo-pituitary-adrenal axis. Pharmacol Exp Ther. 2004;. Epub 309. Available at: http://jpet.aspetjournals.org
186. Fitzgibbon E.J., Hall P., Schroder C., et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: A strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage. 23:2002;165-170
187. Oga K., Kojima T., Matsuura M., et al. Effects of low-dose ketamine on neuropathic pain: An electro-encephalogram-electrooculogram/behavioral study. Psychiatry Clin Neurosci. 56:2002;355-363
188. Noyes R. Jr, Brunk S.F., Baram D.A., Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 15:1975;139-143
189. Jochimsen P.R., Lawton R.L., VerSteeg K., Noyes R. Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther. 24:1978;223-227
190. Staquet M., Gantt C., Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther. 23:1978;397-401
191. Oskarsson P., Ljunggren J.G., Lins P.E. Mexiletine Study Group. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care. 20:1997;1594-1597
192. Wright J.M., Oki J.C., Graves L. III. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother. 31:1997;29-34
193. Morganroth J. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. Am J Cardiol. 60:1987;1276-1281
194. Eisenach J.C., DuPen S., Dubois M., et al. Epidural Clonidine Study Group. Epidural clonidine analgesia for intractable cancer pain. Pain. 61:1995;391-399
195. Gowing L., Farrell M., Ali R., White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2:2003;CD002024
196. Leiphart J.W., Dills C.V., Zikel O.M., et al. A comparison of intrathecally administered narcotic and nonnarcotic analgesics for experimental chronic neuropathic pain. J Neurosurg. 82:1995;595-599
197. Levy R., Leiphart J., Dills C. Analgesic action of acute and chronic intraspinally administered opiate and alpha 2-adrenergic agonists in chronic neuropathic pain. Stereotact Funct Neurosurg. 62:1994;279-289
198. Aboufatima R., Chait A., Dalal A., et al. No tolerance to the antinociceptive action of calcitonin in rats and mice. Neurosci Lett. 359:2004;5-8
199. Amin P., Sturrock N.D. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med. 20:2003;114-118
200. Wiech K., Kiefer R.T., Topfner S., et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg. 98:2004;408-413
201. Nikolajsen L., Gottrup H., Kristensen A.G., Jensen T.S. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: A randomized, double-blinded, cross-over study. Anesth Analg. 91:2000;960-966
202. Taira T., Hori T. Clinical appliction of drug pump for spasticity, pain, and restorative neurosurgery: Other clinical applications of intrathecal baclofen. Acta Neurochir Suppl. 87:2003;37-38
203. Gatscher S., Becker R., Uhle E., Bertalanffy H. Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentation pain. Acta Neurochir Suppl. 79:2002;75-76
204. Shimizu T., Shibata M., Wakisaka S., et al. Intrathecal lithium reduces neuropathic pain responses in a rat model of peripheral neuropathy. Pain. 85:2000;59-64
205. Solaro C., Messmer Uccelli M., Uccelli A., et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 44:2000;45-48
206. Matthews E.A., Dickenson A.H. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 96:2002;633-640
207. Mercandante S., Arcuri E., Tirelli W., et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study. Tumori. 88:2002;239-242
208. Ulugol A., Karadag H.C., Tamer M., et al. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett. 328:2002;129-132
209. Esser M.J., Chase T., Allen G.V., Sawynok J. Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: Multiple interactions. Eur J Pharmacol. 40:2001;211-218
210. Zarrindast M.R., Shaverdian S., Sahebgharani M. Effect of imipramine on tolerance to morphine antinciception in the formalin test. Pharmacol Toxicol. 87:2000;131-137
211. Gordon N.C., Heller P.H., Gear R.W., Levine J.D. Temporal factors in the enhancement of morphine analgesia by desipramine. Pain. 53:1993;273-276
212. Alvaro M., Kumar D., Julka I.S. Transcutaneous electrostimulation: Emerging treatment for diabetic neuropathic pain. Diabetes Technol Ther. 1:1999;77-80
213. Perren F., Buchser E., Chedel D., et al. Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain. Pain. 109:2004;189-194
214. Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: A 20-year literature review. J Neurosurg. 100:(Suppl 3):2004;254-267